LuGENE® Lupus Test Launches to Predict Flares & Drug Targets: Press Release

LuGENE® Lupus Test Launches to Predict Flares & Drug Targets: Press Release

AMPEL BioSolutions announces a breakthrough in personalized precision medicine that will revolutionize the way doctors manage the autoimmune disease Lupus.  Revealed in the peer-reviewed journal Genome Medicine and being made available to patients through a US follow-on study, the LuGENE® blood test forecasts patient flares and drug targets from gene expression utilizing predictive AI.

read more
A Chase for More Precise Brand of Medication

A Chase for More Precise Brand of Medication

Well, you see, more than 95 percent Lupus patients have experienced a flare of symptoms in the last year. Hence, in response, the new LuGENE® test identifies real-time abnormalities leading to inflammation and immune system dysfunction, abnormalities that are especially targetable by medication.

read more

LuGENE® Launches for Lupus

During this interview with Scripps News Network, Dr. Grammer explains how there is currently no way to predict flares or determine which is the most appropriate treatment for an individual lupus patient.  Identifying a therapeutic regimen that stabilizes a patient’s disease course often takes several years of trial and error.

read more
Local Company’s Blood Test Will Change Lupus Care

Local Company’s Blood Test Will Change Lupus Care

A local precision medicine and science company launched a test that will change the way lupus patients get care. AMPEL BioSolutions created a blood test called LuGENE. It will predict if someone is likely to have a lupus flare.

read more

Pin It on Pinterest